Getein Biotech released its 2026 interim report. First-half net profit attributable to the parent was 184 million yuan, up 69.4% year on year. Operating revenue was 555 million yuan, up 8.3% year on year. Net profit attributable to the parent after deducting non-recurring items was 118 million yuan, up 26.6% year on year. Net operating cash flow was 189 million yuan, up 28.1% year on year. In the second quarter, net profit attributable to the parent was 108 million yuan, up 142.7% year on year. The company said sales of core products such as point-of-care testing and chemiluminescence grew significantly, driving revenue higher. At the same time, it completed the transfer of a 56.9766% stake in its subsidiary Wuhan Jingchuan Diagnostic Technology, which had a positive impact on net profit.
Getein Biotech IncFirst-half net profit up 69.4% and Q2 profit up 142.7%, driven by strong sales and a stake transfer gain.
